

Defining the Relationship Between Plasma Glucose and HbA_{1c}

Analysis of glucose profiles and HbA_{1c} in the Diabetes Control and Complications Trial

CURT L. ROHLFING, BES
HSIAO-MEI WIEDMEYER, MS
RANDIE R. LITTLE, PHD

JACK D. ENGLAND
ALETHEA TENNILL, MS
DAVID E. GOLDSTEIN, MD

OBJECTIVE — To define the relationship between HbA_{1c} and plasma glucose (PG) levels in patients with type 1 diabetes using data from the Diabetes Control and Complications Trial (DCCT).

RESEARCH DESIGN AND METHODS — The DCCT was a multicenter, randomized clinical trial designed to compare intensive and conventional therapies and their relative effects on the development and progression of diabetic complications in patients with type 1 diabetes. Quarterly HbA_{1c} and corresponding seven-point capillary blood glucose profiles (premeal, postmeal, and bedtime) obtained in the DCCT were analyzed to define the relationship between HbA_{1c} and PG. Only data from complete profiles with corresponding HbA_{1c} were used ($n = 26,056$). Of the 1,441 subjects who participated in the study, 2 were excluded due to missing data. Mean plasma glucose (MPG) was estimated by multiplying capillary blood glucose by 1.11. Linear regression analysis weighted by the number of observations per subject was used to correlate MPG and HbA_{1c}.

RESULTS — Linear regression analysis, using MPG and HbA_{1c} summarized by patient ($n = 1,439$), produced a relationship of $\text{MPG (mmol/l)} = (1.98 \cdot \text{HbA}_{1c}) - 4.29$ or $\text{MPG (mg/dl)} = (35.6 \cdot \text{HbA}_{1c}) - 77.3$, $r = 0.82$). Among individual time points, afternoon and evening PG (postlunch, predinner, postdinner, and bedtime) showed higher correlations with HbA_{1c} than the morning time points (prebreakfast, postbreakfast, and prelunch).

CONCLUSIONS — We have defined the relationship between HbA_{1c} and PG as assessed in the DCCT. Knowing this relationship can help patients with diabetes and their healthcare providers set day-to-day targets for PG to achieve specific HbA_{1c} goals.

Diabetes Care 25:275–278, 2002

The results of the Diabetes Control and Complications Trial (DCCT), published in 1993, and the U.K. Prospective Diabetes Study, published in 1998, established the relationship between HbA_{1c} levels and risks for diabetic complications in patients with type 1 and type 2 diabetes, respectively. Based on the

results of the DCCT, the American Diabetes Association (ADA) has published recommendations for HbA_{1c} and plasma glucose (PG) levels that are widely used (1,2). However, it is important that the relationship between daily patient-monitored blood glucose determinations and HbA_{1c} be clearly defined to enable

patients and their health care providers to set appropriate daily PG testing goals to achieve HbA_{1c} levels representing low risks for adverse outcomes.

Several previous studies have analyzed the relationship between blood glucose (BG) and HbA_{1c}. Svendsen et al. (3) assessed 15 subjects with type 1 diabetes who collected seven-point BG profiles over a 5-week period (three profiles per week) and used a curvilinear equation to correlate BG and HbA_{1c}. Nathan et al. (4) obtained repeated preprandial and postprandial BG samples from 21 subjects with type 1 diabetes over an 8-week period and used a linear regression equation to describe the relationship between BG and HbA_{1c}. In the DCCT, the correlation between HbA_{1c} and mean BG was initially determined in a limited number of patients ($n = 278$) for the feasibility study (5). However, a comprehensive analysis of the relationship of BG and HbA_{1c}, examining BG at different time points and using the entire data set, was never performed. Here, we examine, in detail, the relationship between BG (converted to PG) and HbA_{1c}, using data obtained from the entire DCCT data set to better define this relationship.

RESEARCH DESIGN AND METHODS

The DCCT data set was provided by the National Institutes of Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health and was prepared by the Data Coordinating Center at George Washington University. The DCCT was a multicenter, randomized clinical trial designed to compare intensive and conventional therapies and their relative effects on the development and progression of diabetic complications in patients with type 1 diabetes (1). The study population consisted of 1,441 patients with type 1 diabetes recruited by 29 centers located throughout the U.S. and Canada. Patients were between 13 and 39 years of age and did not show evidence of severe diabetic complications at the time

From the University of Missouri School of Medicine, Columbia, Missouri.

Address correspondence and reprint requests to Curt L. Rohlfing, University of Missouri–Columbia, Department of Child Health, 1 Hospital Drive M772, Columbia, MO 65203. E-mail: rohlfc@health.missouri.edu.

Received for publication 20 April 2001 and accepted in revised form 18 October 2001.

Abbreviations: ADA, American Diabetes Association; BG, blood glucose; DCCT, Diabetes Control and Complications Trial; MPG, mean plasma glucose; PG, plasma glucose.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

of admission into the study. Intensive therapy consisted of three or more insulin injections daily or use of an insulin pump with the intent of achieving BG values as close to the normal range as possible. Conventional therapy consisted of one or two insulin injections per day. Mean duration of participation was 6.5 years (range 3–9 years).

Quarterly HbA_{1c} measurements (*n* = 37,058) and corresponding BG profiles were obtained from 1,441 subjects. After exclusions due to incomplete profiles, there were 26,056 HbA_{1c} values with corresponding seven-point profiles from 1,439 subjects (an average of 18 HbA_{1c} values and corresponding profiles per patient).

For the seven-point BG profiles, capillary blood hemolysates were collected before meals, 90 min after meals, and at bedtime by patients in the home (6). BG was measured in a central laboratory using a hexokinase enzymatic method (7). Blood for HbA_{1c} analysis was collected by venipuncture. HbA_{1c} was measured in a central laboratory using an ion-exchange high-performance liquid chromatography method (8,9).

Statistical analysis was performed using SAS and SPSS (Chicago, IL). Mean BG was determined using area-under-the-curve analysis (10). For each profile, the seven time points were connected by straight lines over time for a 24-h period, and then the trapezoidal areas under each curve were determined, added together, and divided by time. A constant BG level between bedtime and the following morning was assumed. Mean plasma glucose (MPG) was estimated by adding 11% to mean BG estimates (11). Mean MPG and HbA_{1c} were calculated for each subject and used to perform least-squares linear regression analysis. Due to variation in the number of observations per subject, the regression analysis was weighted to account for this. The relationships between individual PG time points and HbA_{1c} were also examined.

RESULTS — The results of linear regression analysis are summarized in Fig. 1. The Pearson correlation coefficient (*r*) was 0.82; change in MPG per increase of 1% HbA_{1c} was 1.98 mmol/l (35.6 mg/dl). The 95% prediction interval for a subject with 18 observations (the average number of profiles per patient in this study) was ±3.81 mmol/l (69 mg/dl) at levels of




Figure 1—MPG versus HbA_{1c}: *n* = 1,439; *r* = 0.82; $PG \text{ (mmol/l)} = (1.98 \cdot HbA_{1c}) - 4.29$. The dashed line indicates the regression line.

6–9% HbA_{1c}. Within-subject (intraindividual) variation in HbA_{1c} was much lower than for seven-point PG (mean intraindividual coefficient of variation = 9.7 vs. 29.8%, respectively).

MPG at increasing levels of HbA_{1c} is shown in Table 1. Along with regression-estimated MPG, the table shows approximate MPG based on increments of 2 mmol/l or 35 mg/dl per 1% change in HbA_{1c}

Table 1—MPG as estimated from the regression line and approximate MPG (based on MPG change of 35 mg/dl or 2 mmol/l per 1% change in HbA_{1c}) at different HbA_{1c} levels

HbA _{1c} (%)	Regression-estimated MPG		Approximate MPG for clinical use	
	mmol/l	mg/dl	mmol/l	mg/dl
4	3.6	65	3.5	65
5	5.6	101	5.5	100
6	7.6	137	7.5	135
7	9.6	172	9.5	170
8	11.5	208	11.5	205
9	13.5	244	13.5	240
10	15.5	279	15.5	275
11	17.5	315	17.5	310
12	19.5	350	19.5	345

HbA_{1c} to facilitate clinical interpretation and use of these data.

Results of regression analyses correlating HbA_{1c} with individual premeal and postmeal PG are summarized in Figs. 2 and 3. All individual time points showed lower correlations than the seven-point profiles. Prelunch and earlier PG time points showed lower correlations with HbA_{1c} than postlunch and later PG time points.

CONCLUSIONS — The increasing use of HbA_{1c} to monitor long-term glycemic control in diabetic patients is largely the result of data from the DCCT and the U.K. Prospective Diabetes Study showing that HbA_{1c} is strongly correlated with adverse outcome risks. For patients and health care providers, a clear understanding of the relationship between PG and HbA_{1c} is necessary for setting appropriate day-to-day PG testing goals with the expectation of achieving specific HbA_{1c} targets.

The relationship between HbA_{1c} and PG is complex. Many studies have shown that HbA_{1c} is an index of MPG over the preceding weeks to months. Erythrocyte life span averages ~120 days. The level of HbA_{1c} at any point in time is contributed




Figure 2—Premeal MPG and r at different testing times. —, Prebreakfast; ----, prelunch; — · —, predinner; — · — · —, seven-point.

to by all circulating erythrocytes, from the oldest (120 days old) to the youngest. However, recent PG levels (i.e., 3–4 weeks earlier) contribute considerably more to the level of HbA_{1c} than do long-

past PG levels (i.e., 3–4 months earlier). Therefore, HbA_{1c} is a “weighted” average of BG levels during the preceding 120 days; PG levels in the preceding 30 days contribute ~50% to the final result, and

PG levels from 90–120 days earlier contribute only ~10% (12,13). This explains why the level of HbA_{1c} can increase or decrease relatively quickly with large changes in PG; it does not take 120 days to detect a clinically meaningful change in HbA_{1c} after a change in MPG.

Another factor that complicates efforts to describe an accurate and precise relationship between PG and HbA_{1c} is that, for practical reasons, previous studies and our present study have attempted to define this relationship using a limited number of PG levels measured over a limited time period (in this case, 1 day every 3 months) to estimate HbA_{1c}. Short-term PG levels can fluctuate markedly, particularly in patients with type 1 diabetes; this can result in significant discrepancies when attempting to estimate HbA_{1c} based on a single PG measurement or even a series of measurements on a single day. In this study, the time between sampling also contributes to intraindividual variation, especially for PG. However, we have achieved greater certainty in our estimates of the relationship between PG and HbA_{1c} than was possible in previous studies by using a considerably larger number of patients and observations obtained over a longer period of time. The resulting strong correlation suggests that, although a single PG measurement or a single daily profile may not reliably predict HbA_{1c}, PG levels measured over time can provide a reasonably accurate estimation of HbA_{1c}.

Several studies have suggested that, although intraindividual variation in HbA_{1c} is minimal, there is evidence of wide fluctuations in HbA_{1c} between individuals that are unrelated to glycemic status, suggesting that there are “low glycoators” and “high glycoators” (14–16). However, a recent study showed that when multiple observations per patient are used to minimize the effects of assay variation, the interindividual range of HbA_{1c} results in nondiabetic individuals is actually quite narrow, <1% HbA_{1c} (17). Therefore, for any individual patient, a consistent discrepancy between patient-monitored PG determinations and estimated HbA_{1c} should be investigated; there may be other factors causing this discrepancy, such as improper meter use, laboratory error, a physical condition that alters red cell life span, or a variant hemoglobin interfering with the HbA_{1c} assay method. With the advent of new




Figure 3—Postmeal MPG and r at different testing times. —, Postbreakfast; ----, Postlunch; — · —, postdinner; — · — · —, bedtime; —, seven-point.

technologies that are capable of monitoring PG on a 24-h basis (18), it will be interesting to see how our estimate of the relationship between PG and HbA_{1c} compares with estimates obtained using these technologies.

Our data indicate that fasting PG alone should be used with caution as a measure of long-term glycemia. Fasting PG tended to progressively underestimate HbA_{1c} (and seven-point MPG) at increasing PG levels. The data also suggest that postmeal PG contributes appreciably to HbA_{1c}; however, all postmeal times are not equal in their contribution. We found that compared with the seven-point profiles, postbreakfast levels markedly overestimate HbA_{1c}, whereas postlunch levels show a relationship to HbA_{1c} that is very similar to that of MPG. A previous study of patients with type 2 diabetes also found that postlunch PG is a better indicator of glycemic control than fasting PG (19). However, that study did not examine bedtime PG, which we found also shows a relationship to HbA_{1c} that is very similar to that of MPG.

The ADA currently recommends that patients with diabetes attempt to achieve average preprandial PG levels of 5.0–7.2 mmol/l (90–130 mg/dl) and average bedtime PG levels of 6.1–8.3 mmol/l (110–150 mg/dl) as well as HbA_{1c} <7% (2). Our results show estimated average preprandial PG and bedtime PG levels of 8.7 and 9.2 mmol/l (157 and 166 mg/dl), respectively, at 7% HbA_{1c}. These data suggest that patients who consistently achieve ADA-recommended BG and PG targets will also achieve an HbA_{1c} level <7%.

In summary, there is a predictable relationship between PG and HbA_{1c}. Understanding this relationship will allow patients with diabetes and their health-care providers set appropriate day-to-day PG targets based on HbA_{1c} goals. It is important to note that the relationship between PG and HbA_{1c} defined in this study only applies when HbA_{1c} is measured using assay methods that are certified by the National Glycohemoglobin Standardization Program as traceable to the DCCT

reference method, as recommended by the ADA (20). Fasting PG should be used with caution as a surrogate measure of MPG because it may significantly underestimate HbA_{1c} and, therefore, risks for complications at increasing HbA_{1c} levels.

Acknowledgments—We thank the DCCT study group and the Data Coordinating Center at George Washington University for providing the data set as well as the patient volunteers who participated in the DCCT.

References

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in the diabetes control in insulin dependent diabetes mellitus. *N Engl J Med* 329:977–986, 1993
2. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position statement). *Diabetes Care* 24 (Suppl. 1):S33–S43, 2001
3. Svendsen PA, Lauritzen T, Soegaard U, Nerup J: Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. *Diabetologia* 23:403–405, 1982
4. Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical informational value of the glycosylated hemoglobin assay. *N Engl J Med* 310:341–346, 1984
5. The Diabetes Control and Complications Trial Research Group: Diabetes Control and Complications Trial (DCCT): results of feasibility study. *Diabetes Care* 10:1–19, 1987
6. Schlebusch H, Sorger M, Munz E, Kessler A, Zvez WP: Glucosebestimmung in hamolysierten blutproben. *J Clin Chem Clin Biochem* 18:885–891, 1980
7. Neeley WE: Simply automated determination of serum or plasma glucose by a hexokinase/glucose-6-phosphate dehydrogenase method. *Clin Chem* 18:509–515, 1972
8. Dunn PJ, Cole RA, Soeldner JS: Further development and automation of a high-pressure liquid chromatography method for the determination of glycosylated hemoglobins. *Metabolism* 28:777–779, 1979
9. Mosca A, Carpinelli A, Bonini P: Automated determination of glycated hemoglobins with a new high-performance liquid chromatography analyzer. *Clin Chem* 32:202–203, 1986
10. Tai MM: A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. *Diabetes Care* 17:152–154, 1994
11. Fogh-Andersen N, D’Orazio P: Proposal for standardizing direct-reading biosensors for blood glucose. *Clin Chem* 44:655–659, 1998
12. Tahara Y, Shima K: The response of GHb to stepwise plasma glucose change over time in diabetic patients. *Diabetes Care* 16:1313–1314, 1993
13. Goldstein DE, Little RR, Wiedmeyer HM, England JD, Rohlfing CL: Glycohemoglobin testing in diabetes mellitus: assay methods and clinical interpretation. In *Drugs in Development*. Vol. 1. Vasselli JR, Maggio CA, Scriabine A, Eds. Branford, CT, Neva Press, 1993, p. 253–267
14. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ: Unexplained variability of glycated hemoglobin in non-diabetic subjects not related to glycemia. *Diabetologia* 33:208–215, 1990
15. Kilpatrick ES, Maylor PW, Keevil BG: Biological variation of glycated hemoglobin: implications for diabetes screening and monitoring. *Diabetes Care* 21:261–264, 1998
16. Hudson PR, Child DF, Jones H, Williams CP: Differences in rates of glycation (glycation index) may significantly affect individual HbA_{1c} results in type 1 diabetes. *Ann Clin Biochem* 36:451–459, 1999
17. Wiedmeyer HM, Rohlfing CL, Little R, Grotz VL, Tennill A, Goldstein D: Do biological factors other than changes in glycaemic status affect glycohemoglobin results? (Abstract) *Diabetes* 49 (Suppl. 1): A96, 2000
18. Bode BW, Sabbah H, Davidson PC: What’s ahead in glucose monitoring? New techniques hold promise for improved ease and accuracy. *Postgrad Med* 109:41–49, 2001
19. Avignon A, Radauceanu A, Monnier L: Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. *Diabetes Care* 20:1822–1826, 1997
20. American Diabetes Association: Tests of glycemia in diabetes (Position statement). *Diabetes Care* 24 (Suppl. 1):S80–S82, 2001